Novel use for an EGFR mutation‐specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia

Abstract

EGFR mutation-specific antibodies can be used to discriminate between lung ADC and benign pneumocyte hyperplasia, even in small-sized biopsies.

The many facets of diagnostic bronchoscopy for pulmonary ground glass nodules

“…Lung cancer at its beginning stages usually manifests as GGOs on CT scan; due to the fact that pathologic diagnosis of in situ or minimally invasive lung cancer is relatively new, histopathologic examination of small biopsy samples will need expertise and standard protocols (25).…”

Exuberant type 2 pneumocyte hyperplasia: mimic or forerunner of atypical adenomatous hyperplasia?

“…Sir : Recently, we have read with great interest the paper by Mimori et al . concerning the novel use for an epidermal growth factor receptor (EGFR) mutation‐specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia.…”